Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients

Exclusion Criteria

• •1. Prior sever allergy to humanized or mouse derived monoclonal antibody. Unable to receive either lenalidomide or R-CHOP background chemotherapy.
• •2. History of myocardial diseases, such as unstable angina pectoris, acute myocardial infarction within 6 months of enrollment, congenital heart failure NYHA III/IV
• •3. Particular kind of DLBCL，such as primary mediastinal/thymic B-cell lymphoma, EBV positive DLBCL, primary cutaneous large B lymphoma, leg type.
• •4. Presence of CNS involvement
• •5. Having surgeries ≥ grade 2 within 3 weeks of enrollment.
• •6. History or now in the treatment process of other malignancies except cured basal cell carcinoma of skin (melanoma not included), and carcinoma in-situ of uterine cervix.
• •7. More than grade 3 neurotoxicity within 2 two weeks of enrollment
• •8. Receiving any treatment for lymphoma except short use of corticosteroid (no more than 10 days)
• •9. History of deep vein thrombosis or pulmonary embolism within 12 months of enrollment
• •10. Unable or reject to receive antithrombotic treatment
• •11. Presence of active HBV infection (HBsAg positive and HBV-DNA≥ 104), HCV infection, acquired and congenital immunodeficiency diseases include but not limited to HIV
• •12. Pregnant or lactating women
• •13. Previously received organ transplant
• •14. Serious uncontrolled infection
• •15. Having contraindications to the use of large doses of hormone, such as uncontrolled hyperglycemia, gastric ulcer, mental disorder.
• •16. Severe neurol of mental illness, including dementia and epilepsy.
• •17. Drug abuse, medical, psychological or social conditions which may interfering with subjects' participation in the study or evaluation of the results
• •18. Patients considered unsuitable to participate in the study by the researchers